aspirin has been researched along with Day Blindness in 36 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Follow-up study of the 214 surviving patients enrolled originally at the Johns Hopkins Clinical Center for the Early Treatment Diabetic Retinopathy Study (ETDRS), which was a clinical trial designed to evaluate the role of laser photocoagulation and aspirin treatment in patients with diabetic retinopathy." | 5.10 | The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. ( Agrón, E; Chew, EY; Csaky, KG; Ferris, FL; Murphy, RP; Reed, GF; Schachat, AP; Thompson, DJ, 2003) |
| "Aspirin has a well established role in the prevention of arterial thrombosis." | 4.79 | Aspirin in essential thrombocythemia: status quo and quo vadis. ( Bangerter, M; Griesshammer, M; Michiels, JJ; van Vliet, HH, 1997) |
| "In the final regression model, VFD was associated with maternal consumption of aspirin during the current pregnancy, recurring/persistent acidemia during the first 3 postnatal days, cerebral ventriculomegaly seen on neonatal ultrasound, prethreshold retinopathy of prematurity (ROP), and supplemental oxygen and ventilator dependence at 36 weeks post-menstrual age." | 3.81 | Antecedents and correlates of visual field deficits in children born extremely preterm. ( Allred, E; Dammann, O; Holm, M; Leviton, A; Msall, ME; Skranes, J, 2015) |
| "Susac's syndrome is an extremely rare clinical manifestation characterized by the triad of fluctuating sensorineural hearing loss, sudden visual loss and encephalopathy." | 2.41 | [Susac syndrome as a cause of sensorineural hearing loss]. ( Albaladejo Devis, I; Cubillana Herrero, JD; Jiménez Cervantes-Nicolás, JA; Minguez Merlos, N; Rodríguez González-Herrero, B; Soler Valcárcel, A, 2002) |
| "In comparison with transient ischemic attacks in patients with vascular risk factors, the usual neurologic presentation of ET consists of brief attacks of sudden cerebral or visual dysfunction, which can be either well localized or diffuse and entirely nonspecific." | 2.40 | Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin. ( Koudstaal, A; Koudstaal, PJ, 1997) |
| "Associations between retinal vein thrombosis and other systemic disorders have been well documented, but a comprehensive literature search failed to reveal any report of essential thrombocythemia as a cause of central retinal vein thrombosis." | 1.33 | Retinal vein thrombosis as the presenting symptom of essential thrombocythemia. ( Aithal, S; Huang, YW; Marshak, H; Novetsky, A; Saffra, N; Tache, JE, 2005) |
| "To report a case of Dengue fever resulting in permanent visual loss in both eyes due to retinal capillary occlusion." | 1.32 | Ocular manifestations in Dengue fever. ( Campos, WR; de Moraes Figueiredo, LT; Oréfice, F; Siqueira, RC; Vitral, NP, 2004) |
| "Treatment with aspirin and prednisone in one patient." | 1.29 | Anterior ischemic optic neuropathy secondary to interferon alfa. ( Purvin, VA, 1995) |
| "Recurrent transient ischemic attack or amaurosis fugax occurred more frequently (P less than 0." | 1.27 | Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks. ( Eriksson, SE, 1985) |
| "Hallucinations were either unformed (for example, bright lights, straight lines) or highly formed (for example, faces), in which case they were invariably recognized by the patient as inappropriate." | 1.25 | Cerebral disorders of vision in systemic lupus erythematosus. ( Brandt, KD; Cohen, AS; Lessell, S, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (25.00) | 18.7374 |
| 1990's | 8 (22.22) | 18.2507 |
| 2000's | 11 (30.56) | 29.6817 |
| 2010's | 6 (16.67) | 24.3611 |
| 2020's | 2 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Hočevar, A | 1 |
| Ješe, R | 1 |
| Tomšič, M | 1 |
| Rotar, Ž | 1 |
| Stanescu, N | 1 |
| Wood, K | 1 |
| Greenberg, T | 1 |
| Maklakovski, M | 1 |
| Rubinov, A | 1 |
| Dagan, A | 1 |
| Nesher, G | 1 |
| Poltorak, V | 1 |
| Hindi, I | 1 |
| Nesher, R | 1 |
| Dror, Y | 1 |
| Orbach, H | 1 |
| Breuer, GS | 1 |
| Dari, ML | 1 |
| Nguyen, C | 1 |
| Wolfensberger, TJ | 1 |
| Pournaras, JA | 1 |
| Holm, M | 1 |
| Msall, ME | 1 |
| Skranes, J | 1 |
| Dammann, O | 1 |
| Allred, E | 1 |
| Leviton, A | 1 |
| Hughes, WM | 1 |
| Villalon-Gomez, JM | 1 |
| Futch, D | 1 |
| Schneider, MJ | 1 |
| Murphy, D | 1 |
| Grayev, A | 1 |
| Beato, J | 1 |
| Fígueira, L | 1 |
| Penas, S | 1 |
| Santos-Silva, R | 1 |
| Falcão, M | 1 |
| Carneiro, Â | 1 |
| Reis, FF | 1 |
| Stoffelns, BM | 1 |
| Borg, FA | 1 |
| Salter, VL | 1 |
| Dasgupta, B | 1 |
| Berger, CT | 1 |
| Wolbers, M | 1 |
| Meyer, P | 1 |
| Daikeler, T | 1 |
| Hess, C | 1 |
| Dörr, J | 1 |
| Radbruch, H | 1 |
| Bock, M | 1 |
| Wuerfel, J | 1 |
| Brüggemann, A | 1 |
| Wandinger, KP | 1 |
| Zeise, D | 1 |
| Pfueller, CF | 1 |
| Zipp, F | 1 |
| Paul, F | 1 |
| Cubillana Herrero, JD | 1 |
| Soler Valcárcel, A | 1 |
| Albaladejo Devis, I | 1 |
| Rodríguez González-Herrero, B | 1 |
| Minguez Merlos, N | 1 |
| Jiménez Cervantes-Nicolás, JA | 1 |
| Chew, EY | 2 |
| Ferris, FL | 2 |
| Csaky, KG | 1 |
| Murphy, RP | 1 |
| Agrón, E | 1 |
| Thompson, DJ | 1 |
| Reed, GF | 1 |
| Schachat, AP | 1 |
| Siqueira, RC | 1 |
| Vitral, NP | 1 |
| Campos, WR | 1 |
| Oréfice, F | 1 |
| de Moraes Figueiredo, LT | 1 |
| Tache, JE | 1 |
| Saffra, N | 1 |
| Marshak, H | 1 |
| Aithal, S | 1 |
| Novetsky, A | 1 |
| Huang, YW | 1 |
| Löw, U | 1 |
| Kohlhof, JK | 1 |
| Ruprecht, KW | 1 |
| Purvin, VA | 1 |
| Wildemann, B | 1 |
| Schülin, C | 1 |
| Storch-Hagenlocher, B | 1 |
| Hacke, W | 1 |
| Dithmar, S | 1 |
| Kirchhof, K | 1 |
| Jansen, O | 1 |
| Breitbart, A | 1 |
| Michiels, JJ | 2 |
| van Genderen, PJ | 1 |
| Jansen, PH | 1 |
| Koudstaal, PJ | 2 |
| Ferris, F | 1 |
| Koudstaal, A | 1 |
| Griesshammer, M | 1 |
| Bangerter, M | 1 |
| van Vliet, HH | 1 |
| Davis, MD | 1 |
| Fisher, MR | 1 |
| Gangnon, RE | 1 |
| Barton, F | 1 |
| Aiello, LM | 1 |
| Knatterud, GL | 1 |
| Leo-Kottler, B | 1 |
| Klein, R | 1 |
| Berg, PA | 1 |
| Zrenner, E | 1 |
| Nakai, K | 1 |
| Tajima, K | 1 |
| Kishimoto, Y | 1 |
| Katsura, K | 1 |
| Kawamura, M | 1 |
| Yamamoto, Y | 1 |
| Hanada, M | 1 |
| Zen, K | 1 |
| Amakawa, R | 1 |
| Fujimoto, M | 1 |
| Fukuhara, S | 1 |
| McDonald, HR | 1 |
| Marshall, J | 1 |
| Brandt, KD | 1 |
| Lessell, S | 1 |
| Cohen, AS | 1 |
| Levy, NS | 1 |
| Hanscom, T | 1 |
| Wolf, PA | 1 |
| Eriksson, SE | 1 |
| Lamphier, T | 1 |
| Rodriguez, A | 1 |
| Richards, D | 1 |
| Rosner, S | 1 |
| Watillon, M | 1 |
| Robe-Vanwijck, A | 1 |
| Holmes, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (GCA).[NCT00974883] | 880 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| Investigation of Relevant Biomarkers in Patients With Susac Syndrome[NCT01273792] | 30 participants (Anticipated) | Observational | 2010-05-31 | Recruiting | |||
| Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema[NCT05333055] | 150 participants (Anticipated) | Observational | 2022-04-11 | Not yet recruiting | |||
| [NCT00000151] | Phase 3 | 0 participants | Interventional | 1979-12-31 | Completed | ||
| Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial[NCT04708145] | Phase 4 | 150 participants (Anticipated) | Interventional | 2021-06-01 | Active, not recruiting | ||
| Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy[NCT02863354] | Phase 2 | 43 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement[NCT03531294] | Phase 2 | 40 participants (Actual) | Interventional | 2018-05-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in area of retinal capillary non-perfusion outside of the macula from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 weeks and 100 weeks
| Intervention | mm^2 (Mean) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 240.472 | 387.204 |
| Q4WKS | 182.467 | 342.651 |
Change in area of retinal capillary non-perfusion within the macula compared to baseline, as assessed by ultrawide-field fluorescein angiogram from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 weeks and 100 weeks
| Intervention | mm^2 (Mean) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 0.217 | 0.940 |
| Q4WKS | 0.048 | 2.627 |
Change in area of total retinal capillary non-perfusion, as assessed by the central reading center, at week 52 and week 100 compared to baseline. (NCT02863354)
Timeframe: 52 weeks and 100 weeks
| Intervention | mm^2 (Mean) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 66.752 | 245.694 |
| Q4WKS | -11.994 | 141.317 |
Mean change in Early Treatment of Diabetic Retinopathy Study Best Corrected Visual Acuity (ETDRS-BCVA) from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 weeks and 100 weeks
| Intervention | ETDRS letters (Mean) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 4.53 | 8.88 |
| Q4WKS | 4.26 | 4.06 |
Changes in self reported visual function utilizing the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) from baseline to week 52 and week 100. The NEI VFQ is a validated measure of patient-reported visual function measured on a scale from 0 (worst function) to 100 (best function). (NCT02863354)
Timeframe: 52 weeks and 100 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 2.23 | 8.82 |
| Q4WKS | 6.27 | 8.91 |
Mean change in central subfield thickness (CST) from baseline to week 52 and week 100 (NCT02863354)
Timeframe: 52 weeks and 100 weeks
| Intervention | micrometers (Mean) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | -20.813 | -23.313 |
| Q4WKS | -32.947 | -35.059 |
• Assess the safety and tolerability of IAI for the treatment of proliferative diabetic retinopathy by evaluating the incidence and severity of ocular and systemic adverse events through week 52 and week 100. (NCT02863354)
Timeframe: 52 and 100 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 0 | 0 |
| Q4WKS | 0 | 0 |
Percentage of subjects treated with PRP or vitrectomy for progression of PDR from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 0 | 0 |
| Q4WKS | 0 | 0 |
Percentage of subjects, at week 52 and week 100, who develop center-involving diabetic macular edema who did not have center-involving diabetic macular edema at baseline (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 0 | 0 |
| Q4WKS | 0 | 0 |
Percentage of subjects who develop vitreous hemorrhage from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 1 | 1 |
| Q4WKS | 2 | 4 |
Percentage of subjects with increased neovascularization from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 0 | 0 |
| Q4WKS | 1 | 0 |
Percentage of subjects with neovascularization regression (reduced area of neovascularization) as measured by the central image reading center from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 18 | 15 |
| Q4WKS | 17 | 17 |
5 reviews available for aspirin and Day Blindness
| Article | Year |
|---|---|
Neuro-ophthalmic complications in giant cell arteritis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Aspirin; Cytokines; Giant Cell Arteritis; Humans; | 2008 |
[Susac syndrome as a cause of sensorineural hearing loss].
Topics: Adult; Anti-Inflammatory Agents; Aspirin; Cerebral Infarction; Cochlea; Combined Modality Therapy; D | 2002 |
Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders.
Topics: Adult; Aged; Aspirin; Capillaries; Cerebral Arteries; Diagnosis, Differential; Erythromelalgia; Fema | 1996 |
Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Diagnosis, Differential; Erythromelalgia; Headache; Humans; | 1997 |
Aspirin in essential thrombocythemia: status quo and quo vadis.
Topics: Abortion, Habitual; Aspirin; Cerebrovascular Disorders; Cohort Studies; Contraindications; Erythrome | 1997 |
5 trials available for aspirin and Day Blindness
| Article | Year |
|---|---|
The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cataract; Diabetic Retinopathy; Femal | 2003 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18.
Topics: Adolescent; Adult; Aged; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neu | 1998 |
Double-blind study of the analgesic effect of ethoheptazine-aspirin.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Aspirin; Azepines; Clinical Trials as Topic; Depressi | 1974 |
Experimental observations on flufenamic, mefenamic, and meclofenamic acids. IV. Toleration by normal human subjects.
Topics: Adult; Anti-Inflammatory Agents; Aspirin; Biphenyl Compounds; Blood Coagulation; Blood Urea Nitrogen | 1966 |
26 other studies available for aspirin and Day Blindness
| Article | Year |
|---|---|
Risk factors for severe cranial ischaemic complications in giant cell arteritis.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischem | 2020 |
Hemi-central Retinal Artery Occlusion Associated with Giant Cell Arteritis.
Topics: Anti-Inflammatory Agents; Aspirin; Biomarkers; Biopsy; Female; Fluorescein Angiography; Fundus Oculi | 2021 |
Survival of patient with giant cell arteritis: Impact of vision loss and treatment with aspirin.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Giant Cell Arteri | 2019 |
Systematic treatment of central retinal vein occlusion.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Combined Modality Therapy; Folic Acid; Humans; Lig | 2013 |
Antecedents and correlates of visual field deficits in children born extremely preterm.
Topics: Acidosis; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebral Ventricles; Child Develo | 2015 |
Bifrontal headache · blurred vision · vomiting · Dx?
Topics: Aspirin; Clopidogrel; Diagnosis, Differential; Drug Therapy, Combination; Female; Headache; Humans; | 2015 |
Vertebral artery dissection in evolution found during chiropractic examination.
Topics: Adult; Aspirin; Female; Humans; Magnetic Resonance Angiography; Neck Pain; Platelet Aggregation Inhi | 2015 |
Presumed bilateral cilioretinal artery occlusion related to relapsing white dot syndrome.
Topics: Arterial Occlusive Diseases; Aspirin; Ciliary Arteries; Coloring Agents; Drug Therapy, Combination; | 2016 |
[Central Retinal Vein Occlusion accompanied by positive testing of serum antineutrophil cytoplasmic antibodies (c-ANCA)].
Topics: Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Aspirin; Combined Modality Therapy | 2008 |
High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cell Size; Female; Giant Cell Art | 2009 |
Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome.
Topics: Aspirin; Auditory Perceptual Disorders; Brain; Cerebral Angiography; Diagnosis, Differential; Diseas | 2009 |
Ocular manifestations in Dengue fever.
Topics: Adult; Antibodies, Viral; Aspirin; Combined Modality Therapy; Dengue; Dengue Virus; Enzyme-Linked Im | 2004 |
Retinal vein thrombosis as the presenting symptom of essential thrombocythemia.
Topics: Adult; Aspirin; Diagnosis, Differential; Female; Fibrinolytic Agents; Humans; Retinal Vein Occlusion | 2005 |
[Does acetylsalicylic acid have a negative influence on photodynamic therapy?].
Topics: Aged; Aspirin; Choroidal Neovascularization; Drug Combinations; Female; Humans; Macular Degeneration | 2006 |
Anterior ischemic optic neuropathy secondary to interferon alfa.
Topics: Acute Disease; Adult; Aspirin; Carcinoma, Renal Cell; Fundus Oculi; Humans; Interferon-alpha; Ischem | 1995 |
Susac's syndrome: improvement with combined antiplatelet and calcium antagonist therapy.
Topics: Adult; Aspirin; Calcium Channel Blockers; Cerebrovascular Disorders; Drug Combinations; Female; Hear | 1996 |
Ocular symptoms in association with antiphospholipid antibodies.
Topics: Adolescent; Adult; Aged; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Drug Ther | 1998 |
[Bone marrow transplantation-associated thrombotic microangiopathy manifested by visual disturbance].
Topics: Adult; Aspirin; Bone Marrow Transplantation; Dipyridamole; Female; Humans; Leukemia, Myeloid, Acute; | 2000 |
Diagnostic and therapeutic challenges.
Topics: Adult; Aspirin; Female; Fluorescein Angiography; Humans; Plasmapheresis; Prednisone; Purpura, Thromb | 2000 |
Microembolisation as a cause of clinical disorders.
Topics: Aspirin; Humans; Intracranial Embolism and Thrombosis; Ischemic Attack, Transient; Vision Disorders; | 1977 |
Cerebral disorders of vision in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Brain Diseases; Cerebrospinal Fluid; Electroencephalography | 1975 |
Letter: Ibuprofen and visual function.
Topics: Aged; Arthritis, Rheumatoid; Aspirin; Eye; Female; Humans; Ibuprofen; Osteoarthritis; Phenylpropiona | 1976 |
Transient ischemic attacks. Locating the source.
Topics: Aged; Aspirin; Blood Coagulation; Carotid Artery Diseases; Cerebrovascular Circulation; Diagnosis, D | 1985 |
Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks.
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; F | 1985 |
The diagnosis and treatment of cerebral concussion.
Topics: Ascorbic Acid; Aspirin; Brain Concussion; Cerebral Ventriculography; Cortisone; Diphenhydramine; Ele | 1967 |
[Harmful effects of common drugs on the visual apparatus. Minor analgesics, antipyretics, nonsteroid anti-inflammatory and antirheumatic drugs].
Topics: Analgesics; Anti-Inflammatory Agents; Antimalarials; Aspirin; Color Vision Defects; Corneal Opacity; | 1972 |